Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
I3X-MC-JHTB Phase 2 study of gandotinib (LY2784544) in myeloproliferative neoplasms
2024-514254-69-00Phase 2Authorised
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 5
01
Overview
Phase 2, single-arm trial of gandotinib in myeloproliferative disorder (MPD), polycythemia vera (PV), thrombocythemia and 3 more, sponsored by Eli Lilly and Company. Primary endpoint: Objective response rate in MPNs (PV, ET, MF). Planned start Dec 2024; status: authorised.
02
Drugs
gandotinib
03
Conditions
myeloproliferative disorder (MPD)polycythemia vera (PV)thrombocythemiamyelofibrosis (MF)post-polycythemia vera myelofibrosis (PPV-MF)
Beyond the preview
Go deeper on 2024-514254-69-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514254-69-00.